Decnupaz (pivekimab sunirine) coverage guide: the first ADC for blastic plasmacytoid dendritic cell neoplasm

On May 27, 2026, the FDA approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer. Decnupaz is the first and only antibody-drug conjugate (ADC) approved for BPDCN that can be initiated in an outpatient setting, and it marks AbbVie's first ADC approved for a hematologic malignancy.

This coverage guide is for oncology access teams, hematology pharmacists, rare-disease program managers, and payer strategists who need to understand Decnupaz's regulatory status, clinical evidence, safety profile, distribution pathway, and access considerations for this ultra-rare indication.

What Decnupaz is and how it works

Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate. It targets CD123 (IL-3R-alpha), a protein overexpressed on BPDCN cells, and delivers a potent payload from the indolinobenzodiazepine pseudodimer (IGN) class that alkylates DNA and causes single-strand DNA breaks without crosslinking, leading to apoptosis and cell death.

Key parameters:

BPDCN is a rare and aggressive hematologic malignancy with features of both leukemia and lymphoma. It is characterized by skin lesions and can rapidly spread to the bone marrow, lymph nodes, and central nervous system. The disease typically affects adult men aged 60–70 years. Despite initial treatment with intensive chemotherapy, which may include stem cell transplantation, many patients relapse, underscoring the need for new treatment options.

AbbVie acquired pivekimab sunirine through its $10.1 billion buyout of ImmunoGen in 2023, adding BPDCN to its oncology pipeline alongside other ADC assets.

Clinical evidence: CADENZA

The FDA approval was supported by data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of pivekimab sunirine in BPDCN. The trial enrolled two cohorts: treatment-naïve patients and relapsed or refractory patients.

Treatment-naïve BPDCN (n=33):

• Complete remission or clinical complete remission (CR/CRc): 69.7% (95% CI, 51.3%–84.4%)
• Median duration of CR/CRc: 9.7 months (95% CI, 2.9 months to not estimable)
• Median follow-up: 21.5 months
• High and durable response rates enabled eligible patients to proceed to transplant

Relapsed or refractory BPDCN (n=51):

• CR/CRc: 15.7% (95% CI, 7.0%–28.6%)
• Median duration of CR/CRc: 9.2 months (range, 2.7 to 27.6+ months)
• Median follow-up: 24.1 months

CADENZA results were published in the Journal of Clinical Oncology (Pemmaraju N et al., JCO 2026), with data accepted for presentation at the 2026 ASCO Annual Meeting and EHA 2026 Congress.

Principal investigator Naveen Pemmaraju, MD, Professor of Leukemia at MD Anderson Cancer Center, stated that the results suggest pivekimab sunirine should be considered a potential standard treatment for BPDCN in the front-line setting.

Boxed warning and safety profile

The prescribing information includes a Boxed Warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD). Additional warnings and precautions include:

• Infusion-related reactions
• Edema
• Sulfite allergic reactions (formulation contains sulfites)
• Embryo-fetal toxicity

Common adverse events (from CADENZA safety data):

• Peripheral edema: 54% of patients
• Fatigue: 26%
• Infusion-related reactions: 26%
• Nausea: 20%
• Hypokalemia: 20%
• Treatment-related adverse events: 73% (grade 3 or higher in 36%)

Access implications: The boxed warning for hepatotoxicity means payers will require baseline and periodic hepatic function monitoring. Access teams should:

1. Document baseline liver function tests (AST, ALT, bilirubin) before initiating therapy
2. Establish a monitoring schedule aligned with the prescribing information
3. Prepare to submit hepatic function data at each reauthorization

Dosing and administration

The recommended dose is 0.045 mg/kg administered intravenously over approximately 15 to 30 minutes once every three weeks (21-day cycle) until disease progression or unacceptable toxicity. The dose is calculated based on the patient's actual body weight.

Access implications:

• IV administration means buy-and-bill or specialty pharmacy distribution through medical benefit, not pharmacy benefit
• The 21-day cycle may require prior authorization for each cycle or authorization for a defined number of cycles
• Outpatient administration is a differentiator: unlike intensive chemotherapy regimens historically used for BPDCN, Decnupaz does not require inpatient admission

Regulatory designations and context

• Breakthrough Therapy Designation (granted October 2020 for relapsed/refractory BPDCN)
• Orphan Drug Designation
• Priority Review
• The review used the FDA's Assessment Aid, a voluntary submission to facilitate the FDA's assessment

Prior authorization and payer considerations

Because BPDCN is an ultra-rare disease and Decnupaz is the first ADC specifically approved for it, most payers will not have existing coverage policies. Key factors shaping PA criteria:

Expected prior authorization requirements:

• Confirmed diagnosis of BPDCN by pathology (including CD123 expression)
• Prescribed by or in consultation with a hematologist or oncologist experienced in rare hematologic malignancies
• Baseline hepatic function within acceptable limits per prescribing information
• Albumin level ≥3.2 g/dL (precedent from existing BPDCN coverage policies for tagraxofusp)
• For relapsed/refractory patients: documentation of prior therapy and progression
• Acknowledgment of boxed warning for hepatotoxicity and commitment to monitoring

Elzonris (tagraxofusp) precedent: Existing payer coverage policies for tagraxofusp-erzs (Elzonris), the first FDA-approved BPDCN treatment (2018), provide a useful model for Decnupaz PA criteria. Arkansas Blue Cross and other payers require documentation of BPDCN diagnosis, albumin >3.2 g/dL, specialist prescriber, and disease response documentation for continued approval up to 12 months. Decnupaz PA criteria will likely follow a similar framework.

Benefit design considerations:

• Medical benefit (buy-and-bill) for IV administration under physician offices and infusion centers
• J-code assignment is pending; interim billing may use miscellaneous J-codes
• Hospital outpatient departments may bill under APC packaging

Reauthorization: Given the boxed warning and the nature of the disease, payers may require:

• Periodic assessment of hepatic function
• Documentation of continued clinical benefit (imaging, laboratory markers)
• Reauthorization every 2–3 cycles initially, then extending to every 3–6 cycles if response is maintained

Pipeline and expanded indications

AbbVie is evaluating pivekimab sunirine beyond BPDCN:

• Acute myeloid leukemia (AML): Phase 1 study in pediatric patients with relapsed or refractory AML
• Combination in AML: The Phase 2/3 REVIVAL trial is evaluating pivekimab sunirine in combination with venetoclax and azacitidine in adults with AML

If the REVIVAL trial is positive, the addressable population for pivekimab sunirine would expand significantly from ultra-rare BPDCN to AML — a much larger indication.

What to monitor next

1. J-code assignment: Track CMS HCPCS code assignment for billing and reimbursement
2. Specialty pharmacy or distribution network: Confirm whether AbbVie uses a limited distribution model or open network for Decnupaz
3. Patient support program: AbbVie typically launches comprehensive patient support programs alongside oncology launches — monitor for copay assistance, bridge programs, and free-drug programs
4. NCCN guidelines: Track whether NCCN adds pivekimab sunirine to BPDCN treatment guidelines
5. REVIVAL trial (AML): A positive readout would fundamentally change the commercial and access profile
6. Real-world hepatic safety data: Post-marketing surveillance for VOD and hepatotoxicity rates will influence payer confidence and reauthorization policies
7. Skin-response data: EHA 2026 abstracts include data on skin-involved BPDCN patients, which may support broader coverage

Sources

• AbbVie press release: "U.S. FDA Approves DECNUPAZ (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm": https://news.abbvie.com/2026-05-27-U-S-FDA-Approves-DECNUPAZTM-pivekimab-sunirine-pvzy-for-Treatment-of-Adult-Patients-with-Blastic-Plasmacytoid-Dendritic-Cell-Neoplasm,-an-Ultra-Rare-and-Aggressive-Blood-Cancer-With-Limited-Treatment-Options
• FDA Novel Drug Approvals 2026: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• The ASCO Post: "BPDCN: FDA Approves Pivekimab Sunirine-pvzy": https://ascopost.com/news/may-2026/bpdcn-fda-approves-pivekimab-sunirine-pvzy
• Drugs.com Decnupaz FDA Approval History: https://www.drugs.com/history/decnupaz.html
• ONS: "FDA Approves Pivekimab Sunirine-Pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm": https://www.ons.org/publications-research/voice/news-views/05-2026/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
• Pemmaraju N et al. "Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm." J Clin Oncol. 2026
• ClinicalTrials.gov CADENZA: https://clinicaltrials.gov/